Given the favorable results from the IMpower010 clinical trial (NCT02486718, Impower010), atezolizumab has recently been approved as adjuvant therapy following surgery and chemotherapy in patients with stage II to IIIA NSCLC based on PD-L1 expression score using the Ventana PD-L1 assay (SP263, Ventana Medical Systems) as companion diagnostic (72). This evidence concerns the gene CD274 and non-small cell lung carcinoma.